Indicaid Covid-19 Rapid Antigen Test

Ensure the health and safety of your community with our COVID Rapid Antigen Test POC 25-Pack, designed for point-of-care settings. This bulk pack offers: Fast Results: Obtain reliable results in just 15 minutes. High Accuracy: Trusted detection of COVID-19 antigens. Ease of Use: Simple nasal swab procedure with straightforward instructions. Bulk Convenience: Ideal for clinics, workplaces, and events. Perfect for high-volume testing needs, our POC 25-pack ensures efficient and accurate COVID-19 screening.

Ensure rapid, reliable COVID-19 detection with the Indicaid COVID-19 Rapid Antigen Test – the trusted solution for outpatient clinics, workplaces, educational institutions, and healthcare providers across the U.S. This CLIA-waived test offers high sensitivity and specificity, delivering results in just 10 minutes from easy-to-collect nasal swab specimens. Designed for point-of-care (POC) use, the Indicaid test helps detect active SARS-CoV-2 infections, providing an efficient screening tool to control virus spread in real time.

• Fast Results: Get accurate results in just 10 minutes
• Non-Invasive Sampling: Comfortable anterior nasal swab for easy specimen collection
• High Accuracy: 96.0% sensitivity and 99.6% specificity for confident diagnosis
• No Instrument Needed: Easy-to-use, visually readable results without lab equipment
• FDA EUA & CLIA-Waived: Approved for use in authorized settings across the U.S.
• Ideal for Bulk Testing: Efficient for use in healthcare settings, schools, and businesses
• User-Friendly Design: Simple steps with clear visual indicators

• Early Detection of SARS-CoV-2 in symptomatic and asymptomatic individuals
• Routine Screening in clinics, urgent care centers, hospitals, schools & businesses
• Fast Decision-Making in triage and patient management
• Workplace Safety Monitoring for essential service environments
•   Event or Travel Pre-Screening protocols

Q. What is the Indicaid COVID-19 Rapid Antigen Test used for?
A. It’s used for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigen in nasal swabs from individuals suspected of having COVID-19.

Q. How accurate is this test?
A. The test shows 96.0% sensitivity and 99.6% specificity, making it a reliable option for COVID-19 screening.

Q. Is this test FDA approved?
A. The test has received Emergency Use Authorization (EUA) from the FDA for use in CLIA-waived settings.

Q. Who can perform this test?
A. It can be performed by healthcare professionals in point-of-care (POC) settings with CLIA-waived status.

Q. Can this test be used for asymptomatic individuals?
A. Yes, it is authorized for use in both symptomatic and asymptomatic individuals.